The Phase 3 EPCORE DLBCL-4 trial showed that the epcoritamab combination reduced the risk of disease progression by up to 60% in relapsed/refractory DLBCL. Genmab announced positive Phase 3 results for epcoritamab plus lenalidomide, demonstrating a statistically significant improvement in progression-free survival. AbbVie also announced a Phase 3 victory for epcoritamab in relapsed/refractory DLBCL, meeting its primary endpoint.
